Literature DB >> 31094898

Updates on Current Role and Practice of Lung Ablation.

Fereidoun Abtin1, Thierry De Baere2, Damian E Dupuy3, Scott Genshaft1, Terrance Healey3, Sarah Khan1, Robert Suh1.   

Abstract

Interventional oncology and management of thoracic malignancies with ablative techniques are becoming ever more recognized therapeutic options. With increased understanding, development, and utility of the ablative techniques, the indications are expanding and efficacy improving. Lung cancer was among the first indications for lung ablation and remains most challenging with multiple therapeutic options. For inoperable patients, the current literature demonstrates equivalent survivals between ablation, sublobar resection, and stereotactic body radiation. Oligometastatic disease remains the most common indication for lung ablation and is gaining acceptance among the oncology community, as lung ablation provides limited patient downtime, repeatability, and minimal to no loss of respiratory function. Other indications for ablation are being explored, including recurrent mesothelioma, drop metastasis from thymoma, and limited pleural metastasis, with excellent local control of tumor and limited complications. Follow-up after ablation is essential to detect early complications, observe the natural evolution of the ablation zone, and detect recurrence. Standardized imaging follow-up allows for these goals to be achieved and provides a framework for oncology practice. In this article, the role of ablation in the management of thoracic neoplasms and postablation imaging features are reviewed. The radiologists, in particular, thoracic radiologists should be able to identify candidates who can benefit from ablation familiarize themselves with postablation imaging features, and recognize the evolution of the postablation zone and hence detect early recurrence.

Entities:  

Mesh:

Year:  2019        PMID: 31094898     DOI: 10.1097/RTI.0000000000000417

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  8 in total

Review 1.  Cryoablation of Lung Metastases: Review of Recent Literature and Ablation Technique.

Authors:  Patrick W Eiken; Brian T Welch
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

Review 2.  Microwave Ablation in Primary Lung Malignancies.

Authors:  Amgad M Moussa; Etay Ziv; Stephen B Solomon; Juan C Camacho
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

3.  Bronchial Artery Chemoembolization With Radiopaque Doxorubicin Eluding Beads in Patients With Malignant Hemoptysis from Metastatic Lung Cancer.

Authors:  Nariman Nezami; Christos Georgiades; Kelvin K Hong; Ji Buethe
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 4.  The Latest on Lung Ablation.

Authors:  Peyton Cramer; Bradley B Pua
Journal:  Semin Intervent Radiol       Date:  2022-08-31       Impact factor: 1.780

5.  Interstitial Optical Monitoring of Focal Laser Ablation.

Authors:  Rory Geoghegan; Le Zhang; Alan Priester; Holden H Wu; Leonard Marks; Shyam Natarajan
Journal:  IEEE Trans Biomed Eng       Date:  2022-07-18       Impact factor: 4.756

Review 6.  Image-guided percutaneous ablation for the treatment of lung malignancies: current state of the art.

Authors:  Alfredo Páez-Carpio; Fernando M Gómez; Gemma Isus Olivé; Pilar Paredes; Tarik Baetens; Enrique Carrero; Marcelo Sánchez; Ivan Vollmer
Journal:  Insights Imaging       Date:  2021-04-29

Review 7.  Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy.

Authors:  Li Yin; Xing-Yu Li; Lin-Lin Zhu; Gui-Lai Chen; Zhuo Xiang; Qing-Qing Wang; Jing-Wang Bi; Qiang Wang
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

Review 8.  Percutaneous Image-Guided Ablation of Lung Tumors.

Authors:  Sadeer J Alzubaidi; Harris Liou; Gia Saini; Nicole Segaran; J Scott Kriegshauser; Sailendra G Naidu; Indravadan J Patel; Rahmi Oklu
Journal:  J Clin Med       Date:  2021-12-10       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.